DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

Opinion
Video

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Ibrahim Aldoss, MD
D. Ross Camidge, MD, PhD
Related Content
Lung Cancer | Image Credit: © Axel Kock - stock.adobe.com

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16th 2024
Article
Matthew Lunning, DO, FACP, associate professor, the Division of Oncology & Hematology, associate vice chair, research, the Department of Internal Medicine, assistant vice chancellor, clinical research, the University of Nebraska Medical Center

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

March 18th 2024
Podcast
Anne Chiang, MD, PhD, of Yale School of Medicine

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024
Article
Diane M. Simeone, MD; Marwan G. Fakih, MD

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023
Podcast
Shun Lu, MD, PhD

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC

May 13th 2024
Article
Lung Cancer

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024
Article